Healthcare >> CEO Interviews >> February 27, 2006

James Burns – Entremed Inc (enmd)

TWST: EntreMed has long been known as a leader in antiangiogenesis, and

more recently for its multiple mechanism of action drugs for cancer,

such as Panzem' NCD and MKC-1, both of which entered